[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cd19-positive-b-cell-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cd19-positive-b-cell-acute":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100659781","phase-1-blinatumomab-and-inkt-in-relapsed-b-cell-all-100659781",false,"NCT07869368","BLinatumomab and iNKT in Relapsed B-Cell ALL","BLINKB-ALL: BLinatumomab and iNKT in Relapsed B-Cell ALL","BLINK B-ALL","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years.\n* Diagnosis of B-cell ALL.\n* Detection of new MRD positivity after prior MRD negativity, or frank relapse while receiving or after blinatumomab. MRD positivity will be assessed by multiparameter flow\n\nExclusion Criteria:\n\n* Loss of CD19 expressions.\n* Participants with active CNS 3 disease (central nervous system leukemia involvement)\n* Uncontrolled infection\n* Philadelphia positive disease (9;22 translocation at location of BCR-ABL1 fusion)\n* Other concurrent leukemia-directed therapy","ALL","18 Years",{"count":20,"type":21},13,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical care blinatumomab in subjects with Philadelphia chromosome-negative, CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), who have experienced disease progression while receiving blinatumomab, become measurable residual disease (MRD)-positive following prior MRD negativity, or have relapsed disease.\n\nThe primary objective of this study is to assess safety and tolerability of the first planned dose of agenT-797 in combination with blinatumomab. Secondary objectives include evaluating the efficacy of combination therapy and other predefined secondary endpoints. Up to 13 subjects will be enrolled in this study.",[27,28,29,30],"B-Cell ALL","ALL (Acute B-Lymphoblastic Leukemia)","Philadelphia Chromosome-Negative Lymphoblastic Leukemia","CD19-positive B-cell Acute",[32,33,34,35,36,37,38],"Residual disease","disease progression","progressive disease","genT-797","natural killer T-cell (iNKT) therapy","cell therapy","natural killer cell therapy","NOT_YET_RECRUITING","2026-10-06",{"date":42,"type":43},"2026-10-09","ACTUAL",{"date":45,"type":21},"2026-10",{"date":47,"type":21},"2030-02",{"name":49,"class":50},"UNC Lineberger Comprehensive Cancer Center","OTHER"]